Sun Pharmaceutical Industries to Acquire Organon in US$ 11.75 Billion All-Cash Deal

Sun Pharmaceutical Industries to Acquire Organon in US$ 11.75 Billion All-Cash Deal​

Sun Pharmaceutical Industries Limited announced an agreement to acquire Organon & Co., a global healthcare company, in an all-cash transaction valued at US$ 11.75 billion. The deal, announced on April 27, 2026, means Organon stockholders will receive US$ 14.00 per share.

The acquisition, which combines Sun Pharma's global pharmaceutical capabilities with Organon's specialized portfolio, aims to create a more diversified and stronger player in the global pharmaceutical market.

Organon, which was established through a spinoff from Merck in 2021, is a global leader in women's health. Its portfolio includes over 70 products across Women's Health and General Medicines, including biosimilars, marketed in 140 countries. The company operates six manufacturing facilities across the European Union and emerging markets, supporting its scale and reach.

The strategic pairing is set to align with Sun Pharma's focus on growing its Innovative Medicines business, positioning the combined entity as a more robust force in the Established Brands/Branded Generics space.

Transaction and Financial Structure​

Sun Pharma will acquire 100% of Organon's issued and outstanding shares. The transaction's enterprise valuation is US$ 11.75 billion, with the payment structured as an all-cash deal of US$ 14.00 per share.

Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction is structured as a merger of Organon with a subsidiary of Sun Pharma, with Organon remaining the surviving corporation.

The deal is expected to close in early 2027.

For historical context, Organon reported US$ 6.2 billion in revenue and Adjusted EBITDA of US$ 1.9 billion for the year ended December 31, 2025. Organon's consolidated revenue from operations for the previous three years was as follows:

Combined Strengths and Market Impact​

The combined business expects to leverage complementary portfolios and global scale for sustained long-term value creation. The combined entity is projected to achieve several key milestones:

• Becoming among the top 25 global pharmaceutical companies with a combined revenue of US$ 12.4 billion (based on FY24-25 for Sun Pharma and CY2025 for Organon).
• Positioning itself as a leading player in Established Brands/Branded Generics.
• Becoming a more Innovative Medicines focused company with a 27% revenue share.
• Becoming a top 3 company in global Women's Health.
• Becoming the 7th largest global biosimilar player.
• Operating in 150 countries, with 18 large markets, each generating over US$ 100 million in revenues.
• Becoming a stronger cash generating company, with EBITDA and cash flow expected to nearly double, supporting a post-transaction Net Debt/EBITDA of 2.3x.

Management Commentary​

Dilip Shanghvi, Executive Chairman of Sun Pharma, stated, "This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon's portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform."

Kirti Ganorkar, Managing Director of Sun Pharma, added, "Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation."

Carrie Cox, Executive Chair of Organon, noted that the all-cash transaction offers immediate value to Organon stockholders, stating, "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions."

SUNPHARMA Stock Price Movement​

On Friday, Sun Pharmaceutical Industries Limited slipped by 3.67%, shedding ₹61.60 to settle at ₹1620.40. The stock saw heavy trading activity, moving on a volume of 9.61 million shares.